Candriam S.C.A. Sells 255,579 Shares of CG Oncology, Inc. $CGON

Candriam S.C.A. trimmed its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 32.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 542,036 shares of the company’s stock after selling 255,579 shares during the quarter. Candriam S.C.A.’s holdings in CG Oncology were worth $36,685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in CGON. AQR Capital Management LLC bought a new position in shares of CG Oncology during the first quarter valued at about $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after buying an additional 5,442 shares during the last quarter. Millennium Management LLC increased its stake in CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after buying an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of CG Oncology by 42.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after buying an additional 53,461 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of CG Oncology by 12.3% in the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock worth $1,153,000 after buying an additional 4,847 shares during the last quarter. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

NASDAQ CGON traded up $1.92 during trading on Friday, hitting $75.24. 1,042,681 shares of the company’s stock traded hands, compared to its average volume of 1,176,377. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of -32.29 and a beta of 0.22. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $77.00. The business has a 50 day moving average of $64.91 and a 200-day moving average of $60.19.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect that CG Oncology, Inc. will post -2.89 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wedbush increased their price target on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wolfe Research began coverage on CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. Truist Financial reiterated a “buy” rating and set a $82.00 target price (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Finally, Royal Bank Of Canada boosted their price target on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $81.73.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares in the company, valued at approximately $350,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James Mulay sold 1,964 shares of CG Oncology stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the transaction, the director directly owned 654 shares of the company’s stock, valued at $39,318.48. The trade was a 75.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 28,564 shares of company stock valued at $1,986,532 in the last 90 days. 4.80% of the stock is currently owned by company insiders.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.